Document Detail

Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, Mexico.
MedLine Citation:
PMID:  23204848     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: As a first step in the prevention of diabetes, the International Diabetes Federation recommends identification of persons at risk using the Finnish type 2 Diabetes Risk Assessment (FINDRISC) survey. The frequency of diabetes mellitus, impaired fasting glucose, and glucose intolerance in high-risk groups identified by FINDRISC is unknown in our country. The aim of this study was to determine the frequency of diabetes mellitus, impaired fasting glucose, and glucose intolerance in higher-risk groups using a FINDRISC survey in an urban population.
METHODS: We used a television program to invite interested adults to fill out a survey at a television station. An oral glucose tolerance test was performed in all persons with a FINDRISC score ≥ 15 points (high-risk and very high-risk groups). Patients were classified as normal (fasting glucose < 100 mg/dL and 2-hour glucose < 140 mg/dL), or having impaired fasting glucose (fasting glucose 100-125 mg/dL and 2-hour glucose < 140 mg/dL), glucose intolerance (fasting glucose < 126 mg/dL and 2-hour glucose 140-199 mg/dL), and diabetes mellitus (fasting glucose ≥ 126 mg/dL or 2-hour glucose ≥ 200 mg/dL). We describe the frequency of each diagnostic category in this selected population according to gender and age.
RESULTS: A total of 186 patients had a score ≥ 15. The frequencies of diabetes mellitus, impaired fasting glucose, glucose intolerance, and normal glucose levels were 28.6%, 25.9%, 29.2%, and 16.2%, respectively. We found a higher frequency of diabetes mellitus and impaired fasting glucose in men than in women (33% versus 27% and 40% versus 21%, respectively) and more glucose intolerance in women than in men (34% versus 16%, P < 0.05). Patients with diabetes mellitus (52.55 ± 9.2 years) were older than those with impaired fasting glucose (46.19 ± 8.89 years), glucose intolerance (46.15 ± 10.9 years), and normal levels (41.9 ± 10.45 years, P < 0.05). We found a higher frequency of diabetes mellitus in those aged over 50 years than in younger subjects (46.15% versus 15.88%, respectively).
CONCLUSION: The FINDRISC survey is a very useful tool for identifying individuals at high risk of developing diabetes and prediabetic states, especially in those older than 50 years.
Hector García-Alcalá; Christelle Nathalie Genestier-Tamborero; Omara Hirales-Tamez; Jorge Salinas-Palma; Elena Soto-Vega
Related Documents :
25086918 - Effect of fermentation conditions on the flocculation of recombinant saccharomyces cere...
23834678 - Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insuli...
19185258 - Removal of silicone oil droplet adhering to a silicone intraocular lens using 25-gauge ...
25135348 - Genetic variation at glucose and insulin trait loci and response to glucose-insulin-pot...
24728138 - Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in ...
14693978 - Depressive symptoms and risk of type 2 diabetes in women.
Publication Detail:
Type:  Journal Article     Date:  2012-11-19
Journal Detail:
Title:  Diabetes, metabolic syndrome and obesity : targets and therapy     Volume:  5     ISSN:  1178-7007     ISO Abbreviation:  Diabetes Metab Syndr Obes     Publication Date:  2012  
Date Detail:
Created Date:  2012-12-03     Completed Date:  2012-12-04     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101515585     Medline TA:  Diabetes Metab Syndr Obes     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  403-6     Citation Subset:  -    
Faculty of Medicine, Universidad Popular Autónoma del Estado de Puebla, Puebla Pue, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.
Next Document:  Safety and efficacy of personal care products containing colloidal oatmeal.